Patents by Inventor Xiyun Zhang

Xiyun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12286653
    Abstract: The present invention provides engineered carboxyesterase enzymes having improved properties as compared to a naturally occurring wild-type carboxyesterase enzymes, as well as polynucleotides encoding the engineered carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes in amidation reactions.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: April 29, 2025
    Assignee: Codexis, Inc.
    Inventors: Rama Voladri, David Entwistle, Christopher Michael Micklitsch, Vesna Mitchell, Nikki Dellas, Xiyun Zhang, Antoinette Sero, Brent Dorr, Douglas E. Fuerst
  • Patent number: 12286648
    Abstract: The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: April 29, 2025
    Assignee: Codexis, Inc.
    Inventors: Jovana Nazor, Robert Osborne, Jack Liang, Jonathan Vroom, Xiyun Zhang, David Entwistle, Rama Voladri, Ravi David Garcia, Jeffrey C. Moore, Shane Grosser, Birgit Kosjek, Matthew Truppo
  • Patent number: 12263207
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: April 1, 2025
    Assignee: Crosswalk Therapeutics, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • Patent number: 12257291
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Grant
    Filed: May 6, 2024
    Date of Patent: March 25, 2025
    Assignee: Crosswalk Therapeutics, Inc.
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • Publication number: 20250041388
    Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
    Type: Application
    Filed: May 6, 2024
    Publication date: February 6, 2025
    Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
  • Patent number: 12071644
    Abstract: The present invention relates to variant xylanase enzymes and their use thereof.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: August 27, 2024
    Assignee: Fornia Biosolutions, Inc.
    Inventors: Jie Yang, William Buchanan Porterfield, Xiyun Zhang, Goutami Banerjee, Khin Oo, Wenhua Lu
  • Publication number: 20240257907
    Abstract: Systems and methods improving a target property of a target protein are provided. Each single point mutation in a first plurality of single point mutations of the target protein is obtained, each defining a corresponding single point substituted protein with respect to a reference sequence. A set of values for a set of properties of each point substituted protein is used to filter the first plurality of single point mutations into a reduced second plurality of single point mutations. The second plurality of mutations informs the selection of combinatorially substituted proteins and the target property is measured for each of them. The combinatorially substituted proteins and their measured values serve to train a surrogate model that, in turn, serves to update a search model. The updated search mode informs on which of the second plurality point mutations are to be used in future mutants of the target protein.
    Type: Application
    Filed: January 20, 2023
    Publication date: August 1, 2024
    Applicant: BioMetis Technology, Inc.
    Inventors: Jie Yang, Xiyun Zhang, Imad N. Sawaya
  • Patent number: 11987824
    Abstract: The invention is directed to novel variant endoglucanases and their use thereof.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: May 21, 2024
    Assignee: FORNIA BIOSOLUTIONS, INC.
    Inventors: Jie Yang, Xiyun Zhang, William Buchanan Porterfield, Wenhua Lu, Khin Oo, Goutami Banerjee, Tatsuya Fukushima, Eric Lin Hu
  • Publication number: 20240150732
    Abstract: The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds.
    Type: Application
    Filed: January 10, 2024
    Publication date: May 9, 2024
    Inventors: Ish K. Dhawan, Gregory Miller, Xiyun Zhang
  • Patent number: 11939602
    Abstract: The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: March 26, 2024
    Inventors: Ish K. Dhawan, Gregory Miller, Xiyun Zhang
  • Patent number: 11913045
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 27, 2024
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Publication number: 20240026313
    Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
    Type: Application
    Filed: September 28, 2023
    Publication date: January 25, 2024
    Inventors: Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore
  • Patent number: 11807874
    Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: November 7, 2023
    Assignee: Codexis, Inc.
    Inventors: Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore
  • Publication number: 20230272354
    Abstract: The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.
    Type: Application
    Filed: March 8, 2023
    Publication date: August 31, 2023
    Inventors: Jovana Nazor, Robert Osborne, Jack Liang, Jonathan Vroom, Xiyun Zhang, David Entwistle, Rama Voladri, Ravi David Garcia, Jeffrey C. Moore, Shane Grosser, Birgit Kosjek, Matthew Truppo
  • Publication number: 20230250403
    Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
    Type: Application
    Filed: January 12, 2023
    Publication date: August 10, 2023
    Inventors: Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore
  • Publication number: 20230250405
    Abstract: The present invention relates to variant phytase enzymes and their use thereof.
    Type: Application
    Filed: February 9, 2022
    Publication date: August 10, 2023
    Applicant: Fornia BioSolutions, Inc.
    Inventors: Jie Yang, Xiyun Zhang, Yangyuan Li, Jiang Huang
  • Patent number: 11634695
    Abstract: The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: April 25, 2023
    Assignee: Codexis, Inc.
    Inventors: Jovana Nazor, Robert Osborne, Jack Liang, Jonathan Vroom, Xiyun Zhang, David Entwistle, Rama Voladri, Ravi David Garcia, Jeffrey C. Moore, Shane Grosser, Birgit Kosjek, Matthew Truppo
  • Publication number: 20230120624
    Abstract: The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds.
    Type: Application
    Filed: November 30, 2022
    Publication date: April 20, 2023
    Inventors: Ish K. Dhawan, Gregory Miller, Xiyun Zhang
  • Publication number: 20230108132
    Abstract: The invention is directed to novel variant glucoamylases.
    Type: Application
    Filed: July 22, 2022
    Publication date: April 6, 2023
    Applicant: Fornia BioSolutions, Inc.
    Inventors: Xiyun ZHANG, Jie YANG, Goutami BANERJEE, Khin OO, Marielle De Jesus PALATINO, Eric Lin HU, Imad N. SAWAYA, Tatsuya FUKUSHIMA, Jijiao ZENG, Wenhua LU
  • Patent number: 11591578
    Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: February 28, 2023
    Assignee: Codexis, Inc.
    Inventors: Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore